Phase 3Data readout

KarXT (M1/M4 muscarinic agonist)

Schizophrenia, Mental health, Alzheimer's disease

BMYBristol-Myers Squibb

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: KarXT (M1/M4 muscarinic agonist)
Development stage: Phase 3
Event type: Data readout
Indication: Schizophrenia, Mental health, Alzheimer's disease

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for KarXT (M1/M4 muscarinic agonist) in Schizophrenia, Mental health, Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.

Development notes

ADEPT trial. 11/2/23- Initiated ADEPT-2 and ADEPT-3 trials in Q3 '23. Topline data from ADEPT-1 and ADEPT-2 in 2026. 03/18/24- Company acquired by BMY.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

KarXT (M1/M4 muscarinic agonist)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Iberdomide + (daratumumab + dexamethasone)

Camzyos/Mavacamten (MYK-461) (Myosin Inhibitor)

Mezigdomide (CELMoD Modulator)

Izalontamab Brengitecan (BL-B01D1) (EGFR/HER3 Bispecific ADC)